Investors & Media

News

ALL RELEASES

Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results

02/19/20

BERKELEY HEIGHTS, N.J. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2019 financial
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference

02/03/20

BERKELEY HEIGHTS, N.J. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the BIO CEO &
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020

01/13/20

– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML /MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

01/06/20

BERKELEY HEIGHTS, N.J. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech
Read more

PDF Version
Summary Toggle Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

12/09/19

CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies BERKELEY HEIGHTS, N.J. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

11/13/19

– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"),
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

11/07/19

BERKELEY HEIGHTS, N.J. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Wednesday,
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting

11/06/19

BERKELEY HEIGHTS, N.J. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced that data from Cyclacel’s CYC065 and sapacitabine
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

09/23/19

BERKELEY HEIGHTS, N.J. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

09/09/19

BERKELEY HEIGHTS, N.J. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient with an oral
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

09/04/19

BERKELEY HEIGHTS, N.J. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 21st
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results

08/13/19

- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J. , Aug. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results

08/07/19

BERKELEY HEIGHTS, N.J. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2019 financial results on
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients

07/22/19

BERKELEY HEIGHTS, N.J. , July 22, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient in a Phase 1/2 study
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results

05/14/19

Conference Call Scheduled May 14, 2019 at 4:30 p.m. ET BERKELEY HEIGHTS, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results

05/08/19

BERKELEY HEIGHTS, N.J. , May 08, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2019 financial results on
Read more

PDF Version
Summary Toggle Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

04/01/19

-- Clinical benefit in PARP inhibitor-naïve patients supports ongoing Phase 1b/2 IST study of sapacitabine and olaparib combination in BRCA mutant breast cancer -- BERKELEY HEIGHTS, N.J. , April 01, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

03/27/19

– Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J. , March 27, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on cancer cell
Read more

PDF Version
Summary Toggle Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

03/25/19

-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed as the first predictive biomarker of palbociclib efficacy -- BERKELEY HEIGHTS, N.J.
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results

03/20/19

BERKELEY HEIGHTS, N.J. , March 20, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2018 financial
Read more

PDF Version

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter